Opportunity
PIEE #HT9426-27-NOI-049825
Sole-source procurement of two batches of MP201 prodrug for mouse research
Buyer
Defense Health Agency
Posted
November 18, 2026
Respond By
December 31, 2026
Identifier
HT9426-27-NOI-049825
NAICS
541715
DHACA plans a sole-source purchase of Mitochon Pharmaceuticals’ proprietary MP201 for mouse research into Acute Stress Reactions. - Agency and approach: Defense Health Agency Contracting Activity (DHACA), on behalf of WRAIR, CMPN, and ISB, intends to negotiate with Mitochon Pharmaceuticals, Inc. This is a notice of intent to sole source, not a competitive solicitation. - Product: Two freshly synthesized batches of MP201 prodrug for oral administration in mice, supporting dosage development in the approximate range of 8–80 mg/kg body weight. - Requirements: Provide quality-control documentation and dosage background information, plus informational support to the ISB research team preparing MP201-related reports and manuscripts. - Competition: Interested parties may submit capability statements for Government consideration of whether competition is appropriate.
Description
The Defense Health Agency Contracting Activity (DHACA) on behalf of the WRAIR, CMPN, ISB, intends to negotiate on a sole source basis in accordance with RFO 6.103 with vendor Mitochon Pharmaceuticals, Inc. 970 Cross Lane, Blue Bell, PA 19422-1574. The contractor shall supply two (2) Batches of the proprietary prodrug MP201 to ISB for testing Acute Stress Reactions (ASRs). This includes providing quality control documentation and dosage background information. Additionally, the contractor shall provide informational support to the ISB research team by assisting with preparing reports and manuscripts related to MP201. Each batch of synthesized MP201 shall consist of a freshly made lot of prodrug to determine target dosage in the range of approximately 8 - 80 mg/kg body weight. These doses shall be developed in quantities to support oral administration in mice. THIS NOI IS NOT A REQUEST FOR COMPETITIVE PROPOSALS, and no solicitation document exists for this requirement. Meaningful submissions received in response to this notice will be considered solely for the purpose of determining whether a competitive procurement is in the best interest of the Government.. Responsible, interested parties may identify their interest by submitting capability statements (using PDF, MS Word, or Excel attachments), in writing, by 2:00 p.m. Eastern Time, 31 December 2026 to Herbert Keen at herbert.e.keen.civ@health.mil and Mr. Lance Nowell at lance.l.nowell.civ@health.mil. Supporting evidence must be furnished in sufficient detail to demonstrate the firms ability to provide the stated capability. Information and materials submitted in response to this request WILL NOT be returned. DO NOT SUBMIT CLASSIFIED MATERIAL. Responses will be evaluated; however, a determination by the Government not to compete the proposed procurement based upon responses to this notice is solely within the discretion of the Government. If no responses are received, the DHACA will proceed with the sole source contract issued to Mitochon Pharmaceuticals, Inc.